2-Bromo-5-chlorotoluene | CAS:14495-51-3 99.0% bulk supply

We serve 2-Bromo-5-chlorotoluene CAS:14495-51-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Chemical Name:2-Bromo-5-chlorotoluene

CAS.NO:14495-51-3

Synonyms:2-Bromo-5-chlorotoluene

Benzene, 1-bromo-4-chloro-2-methyl-

1-Bromo-4-chloro-2-methylbenzene

Physical and Chemical Properties:

Density 1.5±0.1 g/cm3

Boiling Point 219.1±20.0 °C at 760 mmHg

Molecular Formula C7H6BrCl

Molecular Weight 205.480

Flash Point 95.6±0.0 °C

Specification:

Appearance:Colorless liquid

Assay:≥99.0%

Packing:200 kg/drum, can also be packaged according to customer requirements

Storage:Store in a cool, ventilated place

Application:2-Bromo-5-chlorotoluene is a reagent used in the synthesis of morpholylureas as a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehrydogenase. 2-Bromo-5-chlorotoluene is also used as a reagent in the synthesis of a series of aminopiperidines as novel iNOS inhibitors.

Contact us for information like 2-Bromo-5-chlorotoluene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Bromo-4-chloro-2-methylbenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzene, 1-bromo-4-chloro-2-methyl- Use and application,1-Bromo-4-chloro-2-methylbenzene technical grade,usp/ep/jp grade.

Related News: A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.Bromopyruvic acid manufacturer A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.Chlorodipiperidinocarbenium Hexafluorophosphate supplier A Phase 1/2 trial of the combination therapy has been fully enrolled, and the preliminary efficacy and safety data was presented at The American Society of Hematology (ASH) Annual Meeting in December 2018.1,7-DIIODOHEPTANE vendor Combining its core technological advantages such as ammonia oxidation, phosgenation, and fluorination, the company actively enters the field of fine and functional chemicals, and expands its focus to include polymer additives, replacement of phenolic polymer material monomers, and coating preservatives.Combining its core technological advantages such as ammonia oxidation, phosgenation, and fluorination, the company actively enters the field of fine and functional chemicals, and expands its focus to include polymer additives, replacement of phenolic polymer material monomers, and coating preservatives.